Sodium Valproate
Drugvalproate sustained release minitablets, once daily.
Other names: Orfiril (R) long
NCT Number: NCT00870688
Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets. As a multiple unit dosage form these can be easily swallowed and taken independent from meals.
A simple dosage scheme like valproate sustained release minitablets once daily in the evening should improve the compliance and likely the seizure situation of the patients. The data of this non interventional trial were directly extracted from the physician's electronic patient database. The observational period was 7 weeks compared to a retrospective period 7 weeks before start of the study.
Looking for future studies?
Notify Me12 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
valproate sustained release minitablets, once daily.
Other names: Orfiril (R) long
Time frame: 7 weeks
Time frame: 7 weeks
Time frame: 7 weeks
Desitin Arzneimittel GmbH
Industry
Non Interventional Trial of Valproate Sustained Release Minitablets Once Daily in the Evening
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03817229
Behavior, Brain Diseases
Orange, California, United States
View Trial DetailsNCT00356018
Behavior, Brain Diseases
Orlando, Florida, United States
View Trial DetailsNCT06546410
Brain Diseases, Central Nervous System Diseases
Liverpool, United Kingdom
View Trial DetailsNCT07689084
Brain Diseases, Central Nervous System Diseases
Marburg, Hesse, Germany
View Trial Details